Gene expression profiling of breast cancer to select women for adjuvant chemotherapy

BlueCross BlueShield Association

Citation

Authors' objectives
This Assessment examines whether, compared to conventional risk assessment tools, the use of gene expression profiling improves outcomes when used to decide whether risk of recurrence is low enough to forego adjuvant chemotherapy for early stage breast cancer.

Timeliness warning
This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly.

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Breast Neoplasms /drug therapy /genetics; Chemotherapy, Adjuvant; Device Approval; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic /drug effects /genetics; Neoplasm Recurrence, Local /genetics; Patient Selection; Risk Factors; Treatment Outcome

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA.
Tel: 888 832 4321 Email: tec@bcbsa.com

AccessionNumber
32010000212

Date abstract record published
24/03/2010